InsiderSignalSign in
← Insider buys

FULC

Fulcrum Therapeutics, Inc. · Healthcare

Insiders bought $1.5M of Fulcrum Therapeutics, Inc. in the last 12 months

1 insider bought on 2 days.

$1.5MBought, 12 mo
$58.7MSold, 12 mo
$281.1MMarket cap
Follow FULC

FULC over the last year

Insider buy filed (2 days)

Largest buyers, last 12 months

FULC after insider buys

3 months after each buy, from the first price a copier could get.

−55.5%Average
−59.3 ptsVs S&P 500
0 of 4Higher

4 buys since 2022 with 3 months of prices.

Every filing

41 insider filings since 2020, newest first

FULCBuy

Kevin Tang · 10% owner

$595K+2.4%Jul 21
FULCBuy

Kevin Tang · 10% owner

$891K+3.8%Jul 15
FULCSell

Alan Ezekowitz · Director

$66K−62.2%Jun 30
FULCSell

Robert J Gould · Director

$178K−3.0%Jan 6
FULCSell

Curtis Gale Oltmans · General Counsel

$45K−25.0%Dec 17
FULCSell

Ra Capital Management, L.P. · 10% owner

$58.4M−41.0%Dec 10
FULCSell

Greg Tourangeau · VP, Finance

$57K−29.0%Mar 8
FULCBuy

Alex Sapir · Insider

$492KMar 5
FULCBuy

Ra Capital Management, L.P. · 10% owner

$25.0M+20.0%Jan 24
FULCSell

Robert J Gould · Interim Pres, CEO

$101K−1.0%Jan 13
FULCBuy

Ra Capital Management, L.P. · 10% owner

$1.3M+2.0%Jan 6
FULCBuy

Ra Capital Management, L.P. · 10% owner

$13.1M+34.0%Dec 16
FULCSell

Robert J Gould · Director

$578K−12.0%Jun 8
FULCSell

Robert J Gould · Director

$533K−12.0%Jun 6
FULCSell

Robert J Gould · Director

$135K−1.0%Apr 11
FULCSell

Robert J Gould · Director

$2.3M−16.0%Apr 5
FULCSell

Christopher Moxham · Chief Scientific Officer

$911K−63.0%Aug 12
FULCSell

Bryan Stuart · Insider

$1.2M−100.0%Aug 12
FULCSell

Robert J Gould · Insider

$122K−2.0%Mar 17
FULCSell

Peter G. Thomson · VP Finance, Accounting

$74K−25.0%Feb 24
FULCSell

Robert J Gould · Insider

$117K−2.0%Feb 18
FULCSell

Peter G. Thomson · VP Finance, Accounting

$92K−30.0%Jan 25
FULCSell

Robert J Gould · Insider

$121K−2.0%Jan 22
FULCSell

Owen B. Wallace · Chief Scientific Officer

$59K−2.0%Jul 9
FULCSell

Robert J Gould · Insider

$50KJul 9
FULCSell

Diego Cadavid · SVP Clinical Development

$32K−2.0%Jun 26
FULCSell

Robert J Gould · Insider

$52KJun 26
FULCSell

Robert J Gould · Insider

$69K−1.0%Jun 9
FULCSell

Robert J Gould · Insider

$56K−1.0%Jun 5
FULCSell

Robert J Gould · Insider

$56K−1.0%Jun 3
FULCSell

Robert J Gould · Insider

$66K−1.0%Jun 1
FULCSell

Owen B. Wallace · Chief Scientific Officer

$45K−2.0%Jun 1
FULCSell

Robert J Gould · Insider

$50KMay 28
FULCSell

Diego Cadavid · SVP Clinical Development

$33K−3.0%May 12
FULCSell

Peter G. Thomson · VP Finance, Accounting

$120K−26.0%May 12
FULCSell

Diego Cadavid · SVP Clinical Development

$37K−3.0%Mar 2
FULCSell

Peter G. Thomson · VP Finance, Accounting

$84K−15.0%Feb 26
FULCSell

Robert J Gould · Insider

$50KFeb 20
FULCSell

Owen B. Wallace · Chief Scientific Officer

$122K−5.0%Feb 20
FULCSell

Diego Cadavid · SVP Clinical Development

$37K−3.0%Feb 5
FULCSell

Peter G. Thomson · VP Finance, Accounting

$86K−13.0%Jan 27
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.